The University of California, San Francisco, School of Medicine, and the Children’s Hospital of Philadelphia are pleased to present the 2nd Biennial Pediatric Precision Medicine Cancer Care Summit: Personalizing Pediatric Cancer Care: Innovation through Collaboration
March 22 - 23, 2024
Grand Hyatt San Francisco
San Francisco, CA
Course# MMJ24049
Department: Pediatrics/Center for Cancer, Blood Disorders and Cellular Therapy
Registration Fees
Physicians $450.00
Advanced Practice Professionals $400.00
Clinical Geneticists, PhD Researchers, Laboratory Professionals, Others $150.00
Residents/Fellows/Students $150.00
Cancellation Policy
Cancellations received in writing before March 7, 2024 will be refunded, less a $100 administrative fee. No refunds will be made on cancellations received after that date.
Please email your requests to [email protected]
Call For Abstracts
We invite you to consider submitting an abstract for our summit.
Abstract Submission Deadline:
March 3, 2024, 11:59pm
Submit abstracts via link below:
SAVE THE DATE
Mark your calendar to join your colleagues at the Pediatric Precision Cancer Medicine Summit.
Grand Hyatt San Francisco
San Francisco - March 22-23, 2024
The summit brings together leading experts to discuss the latest breakthroughs in precision medicine and how these advances are changing the landscape of pediatric cancer care, research and precision-based oncology.
CME credits will be available.
More details to come, check back soon. Course outline can be viewed below.
Overview
Continuing in the spirit of innovation through collaboration, we are pleased to invite you to the second Personalizing Pediatric Cancer Care summit, cohosted by UCSF Benioff Children’s Hospitals and Children’s Hospital of Philadelphia. Join us for an enlightening exploration of the latest advances in precision medicine and how they are reshaping the landscape of pediatric cancer care, research and precision-based oncology.
The inaugural summit in Philadelphia was a resounding success, and our organizations are excited to continue the tradition of alternating between the east and west coasts for this biennial event. We look forward to seeing you in San Francisco!
Join other physicians, care providers, clinical geneticists, laboratory leaders and researchers to learn about the latest developments, including:
- Hematological malignancies
- CNS malignancies
- Solid malignancies
- Cancer predisposition
- Advances in lab diagnostics and genetics
- FDA/regulatory updates
- Patient advocacy
TARGET AUDIENCE
Physicians, Nurse Practitioners, Physician Assistants, Nurses, Clinical Geneticists, PhD Researchers, Laboratory Professionals
Objectives
- Articulate the significance of recent advances in liquid biopsies, demonstrating their application in measuring minimal residual disease and early detection of relapse.
- Investigate and appraise new therapeutic opportunities for patients in the relapsed setting using next-generation sequencing panels, while critically assessing the limitations of this technology.
- Analyze and differentiate the frequency and diversity of germline alterations relevant to cancer diagnosis in children and young adults.
- Apply knowledge of germline alterations to implement precise screening practices for patients with cancer and their families.
- Evaluate and address current barriers impeding the widespread use of immunotherapy in pediatric cancer.
- Recognize and assess the emerging importance of CART and other cell therapies in pediatric cancer.
Accreditation
In support of improving patient care, the University of California, San Francisco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians: UCSF designates this live activity for a maximum of 13.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity meets the requirements under California Assembly Bill 1195, continuing education and cultural and linguistic competency.
Nurse Practitioners and Registered Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME. This course is also available for 13.50 Nurse Contact Hours as designated by the ANCC.
Physician Assistants: The National Commission on Certification of Physician Assistants (NCCPA) states that AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.
Course Outline
| Friday, March 22, 2024 | ||
| 7:00AM | Registration and Breakfast | |
| 7:45 | Welcome and Overview | Alejandro Sweet-Cordero, MD UCSF Benioff Children’s Hospitals |
| John Maris, MD Children’s Hospital of Philadelphia |
||
| Session A: Next Generation Diagnostics | ||
| 8:00 | Cancer Gene Panel Testing in Pediatric Populations: The UCSF Experience | Jessica Van Ziffle, PhD, FACMG UCSF |
| 8:30 | Liquid Biopsy for Neuroblastoma | Lea Surrey, MD Children’s Hospital of Philadelphia |
| 9:00 | Towards Mapping Drug Resistance Heritability in Pediatric ALL | Charles Gawad, MD, PhD Stanford University |
| 9:30 | Coffee Break | |
| 9:45 | Integrated Analysis of Methylation and Transcription in Pediatric AML | Benjamin Huang, MD UCSF Benioff Children’s Hospitals |
| 10:15 |
Multi-pronged Precision Approaches to Target the ALK |
Yael Mossé. MD Children's Hospital of Philadelphia |
| Session B: Clinical Trials | ||
| 10:45 | Leveraging International Collaborations to Improve Outcomes in JMML | Elliot Stieglitz, MD UCSF Benioff Children’s Hospitals |
| 11:15 | Precision Medicine for Rare Pediatric Cancers: Lessons Learned and Future Directions | Ted Laetsch, MD Children's Hospital of Philadelphia |
| 11:45 | LUNCH | |
| 1:00PM | An International, Multi-disciplinary, and Multi-faceted Approach to Advancing Precision-based Care for Pediatric CNS Tumors | Cassie Kline, MD, MAS Children's Hospital of Philadelphia |
| 1:30 | Leveraging Real-world Data to Advance Immunotherapy Outcomes |
Liora Schultz, MD Stanford University |
| 2:00 | Biopharma Approaches to Targeted Drug Therapy Development in Pediatric Oncology | Mark Kieran, MD, PhD Day One Bio |
| 2:30 | Coffee Break | |
| Session C: Non-Catalytic Oncogenic Targeting | ||
| 2:45 | Targeting Oncogenic N-myc Complexes in High-risk Pediatric Neural Tumors | Bo Qiu, MD, PhD UCSF Benioff Children’s Hospitals |
| 3:15 | Targeting Translational Control of PAX3-FOXO1 | Amit J. Sabnis, MD UCSF Benioff Children’s Hospitals |
| 3:45 | Targeted Protein Degradation of Pediatric Oncoproteins: Strategies and Progress | Gwenn Hansen, PhD Nurix |
| 4:15 | Coffee Break | |
| 4:30 | Understanding the Pathogenesis and Developing Therapeutics for Fibrolamellar Carcinoma | Sanford M. Simon, PhD Rockefeller University; The Fibrolamellar Registry |
| 5:00 | Pax3:Foxo1 Targeting Genetically and Via Multiple Pharmacological Approaches for Clinical Investigation | Charles Keller, MD Children's Cancer Therapy Development Institute |
| 5:30 | Adjourn | |
| 5:45PM | Reception/Poster Session | |
| Saturday, March 23, 2023 | ||
| 7:00AM | Breakfast | |
| Session D: Cancer Predisposition | ||
| 8:00 | Replication Repair Deficiency in Brain Tumors: Linking Causes with Therapy | Uri Tabori, MD The Hospital for Sick Children |
| 8:30 | Unraveling the Genetic Basis of Neuroblastoma: Recent Findings, Future Directions, and Translational Opportunities | Sharon Diskin, PhD Children's Hospital of Philadelphia |
| 9:00 | The Diagnosis and Long-term Care of Children with a Hereditary Predisposition to Cancer. | Nicola Cadenas, MS, CGC UCSF Benioff Children’s Hospitals |
| 9:30 | Coffee Break | |
| 9:45 | Risk Stratification to Personalize Therapy for Neurofibromatosis Type 1-Associated Tumors | Chelsea Kotch, MD MSCE Children’s Hospital of Philadelphia |
| 10:15 | Targeted Therapies for Neurofibromatosis Associated Tumors: a Genomic Medicine Footprint | Alyssa T. Reddy, MD UCSF Benioff Children's Hospital |
| 10:45 | Coffee Break | |
| Session E: Immunotherapies | ||
| 11:00 | Targeting Intracellular Proteins through MHC 1 for Cancer Applications | Charles Craik, MD UCSF |
| 11:30 | Advances in the Molecular Pathogenesis of Pediatric Brain Tumors | David Solomon, MD, PhD UCSF |
| 12:00PM | Proteomic Strategies to Uncover Cellular Therapy Targets for Refractory Pediatric Hematologic Malignancies | Arun Wiita, MD UCSF |
| 12:30 | LUNCH | |
| 1:45 | Developing GPC2-directed Immunotherapies for Pediatric Cancers | Kristopher Bosse, MD Children's Hospital of Philadelphia |
| 2:15 | CAR T Cell Therapy for CNS Malignancies | Jessica Foster, MD Children’s Hospital of Philadelphia |
| 2:45 | Novel Strategies of Targeting Tumor Antigens In Adult and Pediatric Glioma | Hideho Okada, MD, PhD UCSF |
| 3:15 | Closing Remarks | Alejandro Sweet-Cordero, MD UCSF Benioff Children’s Hospitals |
| John Maris, MD Children’s Hospital of Philadelphia |
||
| 3:30PM | Adjourn | |
Course Chairs
Alejandro Sweet-Cordero, MD
UCSF Benioff Children’s Hospitals
Professor of Pediatrics
John M. Maris, MD
Children’s Hospital of Philadelphia
Giulio D'Angio Professor of Pediatric Oncology
Perelman School of Medicine at the University of Pennsylvania
Joey Mack
UCSF Benioff Children’s Hospitals
Service Line Director, CCBDCT
UCSF Faculty
Nicola Cadenas, MS, CGC
Charles Craik, PhD
Benjamin Huang, MD
Bo Qiu, MD, PhD
Alyssa T. Reddy, MD
Amit J. Sabnis, MD
David Solomon, MD, PhD
Elliot Stieglitz, MD
Jessica Van Ziffle, PhD, FACMG
Guest Faculty
Kristopher Bosse, MD
Sharon Diskin, PhD
Jessica Foster, MD
Charles Gawad, MD, PhD
Gwenn Hansen, PhD
Charles Keller, MD
Mark Kieran, MD, PhD
Cassie Kline, MD, MAS
Chelsea Kotch, MD, MSCE
Theodore W. Laetsch, MD
Yael Mosse, MD
Hideho Okada, MD, PhD
Liora Schultz, MD
Sanford Simon, PhD
Lea Surrey, MD
Uri Tabori, MD
Arun Wiita, MD, PhD
Travel & Lodging
Grand Hyatt San Francisco
345 Stockton Street
San Francisco, CA 94108
Online Reservations Available Here
The last day to reserve the rooms at the group rate is on March 7, 2024
UNITED AIRLINES
UCSF has negotiated special fares with United Airlines for our course attendees. Download Online Booking Instructions (.pdf)
Code ZMGE963115
Exhibitors
Standard Exhibit Fee: $3,500
Email Contact for Exhibits [email protected]
Pay Standard Exhibitor rate by credit card
Note this link cannot be used for “elevated opportunities” – it is only for the standard exhibitor rate of $3,500.
Standard Exhibitor Description
Exhibitors receive the following benefits:
- (1) 6’ x 30” tabletop exhibit space at UCSF assigned location in exhibit hall
- Acknowledgement in the course syllabus distributed to each registrant*
- (2) complimentary exhibitor attendees and (1) copy of the course syllabus
Elevated Opportunities - Exhibitor Tiers
Exhibit Hours
(subject to updating)
EXHIBIT HOURS (subject to updating)
| Friday, March 22, 2024 | |
| 7:00- 8:00AM | Exhibit Area open during Registration |
| 9:30- 10:30AM | Coffee Break in Exhibit Area |
| 11:45AM – 1:00 PM | Provided lunch |
| 3:00- 3:30PM | Coffee Break in Exhibit Area |
| Saturday, March 23, 2024 | |
| 7:00- 8:00AM | Continental Breakfast in Exhibit Area |
| 9:30- 10:30AM | Coffee Break in Exhibit Area |
| 12:30- 1:45PM | Provided lunch |